See more : Propellus Inc. (PRPS) Income Statement Analysis – Financial Results
Complete financial analysis of MediWound Ltd. (MDWD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MediWound Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CIL Nova Petrochemicals Limited (CNOVAPETRO.NS) Income Statement Analysis – Financial Results
- Tekcore Co., Ltd (3339.TWO) Income Statement Analysis – Financial Results
- Gestamp Automoción, S.A. (GMPUF) Income Statement Analysis – Financial Results
- EVN AG (0EEI.L) Income Statement Analysis – Financial Results
- Cawachi Limited (2664.T) Income Statement Analysis – Financial Results
MediWound Ltd. (MDWD)
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.69M | 26.50M | 23.76M | 21.76M | 31.79M | 3.40M | 2.50M | 1.56M | 601.00K | 259.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.11M | 13.33M | 14.99M | 14.22M | 11.85M | 2.09M | 1.58M | 2.16M | 2.52M | 2.79M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.58M | 13.17M | 8.77M | 7.55M | 19.94M | 1.31M | 918.00K | -600.00K | -1.92M | -2.53M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 19.15% | 49.69% | 36.91% | 34.67% | 62.73% | 38.61% | 36.78% | -38.51% | -319.13% | -975.29% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.47M | 10.18M | 10.26M | 7.70M | 4.97M | 4.07M | 5.46M | 7.07M | 6.02M | 5.35M | 3.64M | 1.56M | 3.02M |
| General & Administrative | 8.57M | 8.33M | 6.11M | 8.69M | 9.31M | 7.99M | 9.14M | 12.49M | 13.29M | 4.72M | 1.63M | 1.14M | 1.24M |
| Selling & Marketing | 2.80M | 2.04M | 3.39M | 3.23M | 4.06M | 4.19M | 5.36M | 8.40M | 9.28M | 8.83M | 2.26M | 0.00 | 0.00 |
| SG&A | 11.38M | 10.37M | 9.74M | 8.69M | 9.31M | 7.99M | 9.14M | 12.49M | 13.29M | 13.55M | 3.89M | 1.14M | 1.24M |
| Other Expenses | 24.00K | 958.00K | -710.00K | -144.00K | 1.17M | -751.00K | 56.00K | 66.00K | 59.00K | 49.00K | 57.00K | 33.00K | 24.00K |
| Operating Expenses | 18.87M | 21.51M | 19.99M | 16.39M | 15.45M | 5.27M | 14.61M | 19.56M | 19.31M | 18.90M | 7.58M | 2.73M | 4.29M |
| Cost & Expenses | 33.98M | 34.84M | 34.98M | 30.60M | 27.30M | 7.36M | 16.18M | 21.71M | 21.83M | 21.69M | 7.58M | 2.73M | 4.29M |
| Interest Income | 2.34M | 270.00K | 11.00K | 297.00K | 434.00K | 412.00K | 0.00 | 1.27M | 288.00K | 4.67M | 1.00K | 6.00K | 32.00K |
| Interest Expense | 427.00K | 8.92M | 903.00K | 832.00K | 925.00K | 892.00K | 478.00K | 847.00K | 444.00K | 2.11M | 2.44M | 673.00K | 591.00K |
| Depreciation & Amortization | 1.30M | 1.27M | 1.24M | 1.09M | 1.15M | 577.00K | 567.00K | 589.00K | 503.00K | 492.00K | 336.00K | 267.00K | 196.00K |
| EBITDA | -4.89M | -18.09M | -11.22M | -7.75M | 3.42M | -5.09M | -13.12M | -18.30M | -20.72M | -18.33M | -6.50M | 12.25M | -4.10M |
| EBITDA Ratio | -26.19% | -35.22% | -42.01% | -35.61% | 17.75% | -99.47% | -525.64% | -1,255.84% | -3,448.25% | -6,281.85% | 0.00% | 0.00% | 0.00% |
| Operating Income | -15.29M | -8.35M | -11.22M | -8.84M | 4.49M | -3.96M | -13.69M | -20.16M | -21.23M | -21.43M | -7.58M | -2.73M | -4.29M |
| Operating Income Ratio | -81.83% | -31.50% | -47.22% | -40.62% | 14.13% | -116.44% | -548.36% | -1,293.65% | -3,531.95% | -8,272.97% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.76M | -11.18M | -2.30M | -436.00K | -2.43M | -1.71M | -846.00K | 1.27M | -444.00K | 2.55M | -920.00K | 14.72M | -532.00K |
| Income Before Tax | -6.53M | -19.52M | -13.52M | -9.28M | 2.07M | -5.67M | -14.53M | -18.89M | -21.67M | -18.88M | -8.50M | 11.99M | -4.82M |
| Income Before Tax Ratio | -34.95% | -73.68% | -56.91% | -42.62% | 6.50% | -166.57% | -582.25% | -1,212.13% | -3,605.82% | -7,287.64% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 185.00K | 78.00K | 27.00K | 325.00K | -1.65M | -9.69M | 8.46M | -1.27M | 861.00K | -2.55M | 7.77M | -13.67M | 1.88M |
| Net Income | -6.72M | -19.60M | -13.55M | -9.60M | 3.72M | -1.06M | -22.15M | -18.89M | -22.09M | -18.88M | -15.35M | 10.94M | -6.17M |
| Net Income Ratio | -35.94% | -73.97% | -57.03% | -44.12% | 11.70% | -31.08% | -887.38% | -1,212.13% | -3,675.21% | -7,287.64% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -3.93 | -3.48 | -2.47 | 0.96 | -0.27 | -6.64 | -6.05 | -7.13 | -6.65 | -5.28 | 3.76 | -2.12 |
| EPS Diluted | -0.75 | -3.93 | -3.48 | -2.47 | 0.96 | -0.27 | -6.64 | -6.05 | -7.13 | -6.65 | -5.28 | 3.76 | -2.12 |
| Weighted Avg Shares Out | 9.01M | 4.99M | 3.89M | 3.89M | 3.88M | 3.87M | 3.33M | 3.12M | 3.10M | 2.84M | 2.91M | 2.91M | 2.91M |
| Weighted Avg Shares Out (Dil) | 9.01M | 4.99M | 3.89M | 3.89M | 3.88M | 3.87M | 3.33M | 3.12M | 3.10M | 2.84M | 2.91M | 2.91M | 2.91M |
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients
MediWound to Report Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time
Can MediWound (MDWD) Climb 57.49% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 57.5% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs)
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd
GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (Nasdaq: MDWD) (MediWound) through a definitive...
MediWound Announces $25 Million Strategic Private Placement Financing
Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment
MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD ) Q1 2024 Earnings Conference Call May 29, 2024 8:30 AM ET Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy, Corporate Development Daniel...
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.44 per share a year ago.
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference...
Source: https://incomestatements.info
Category: Stock Reports